TRA-1-81 Antibody, anti-human, REAfinity™
Synonyms: PODXL, Gp200, PC, PCLP, PCLP-1, Podocalyxin
RECOMBINANT
Bioz Star94/100 Bioz rating
12 Citations1 Image
Clone:
REA246 | TRA-1-81
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, ICC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for TRA-1-81 Antibody, anti-human, REAfinity™

Flow cytometry applications
PE
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
PE
Used products:
130-123-293, 130-123-334
Description:
Viral human induced pluripotent stem cells were either left unstained (left peak) or stained with Anti-TRA-1-81 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application image
Immunocytochemistry applications
Vio 488
Data source:
Miltenyi Biotec
Conjugate:
Vio 488
Used products:
130-106-873
Specifications for TRA-1-81 Antibody, anti-human, REAfinity™
Overview

Clone REA246 recognizes a carbohydrate epitope expressed on podocalyxin, which is a transmembrane sialoglycoprotein. Podocalyxin is a member of the CD34-related family of sialomucins and is recognized as a stem cell and malignancy marker. The expression of TRA-1-81 antigen is stage-specific and is lost upon differentiation of human EC and ES cells, making it a marker of undifferentiated pluripotent ES cells.

Additional information: Clone REA246 displays negligible binding to Fc receptors.

Alternative names

PODXL, Gp200, PC, PCLP, PCLP-1, Podocalyxin

Detailed product information

Technical specifications

Clone
REA246
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
TRA-1-81
Molecular mass of antigen [kDa]
56
Distribution of antigen
stem cells, ES and iPS cells
Entrez Gene ID
RRID
AB_2654231, AB_2802023, AB_2802035

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for TRA-1-81 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?